FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Commercial · sales Approved for Korea's first in-house CAR-T therapy, it is starting commercialisation at major hospitals. Also seen: Early clinical · first deals

  • Korean marketing approval of the CAR-T therapy Limkato. Source

Roles often seen at this stageManufacturing & MSAT · Sales & marketing · Medical & MSL

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Curocell

A CAR-T cell-therapy developer that received approval for the first CAR-T therapy developed in-house by a Korean company.

Limkato (anbalcabtagene autoleucel)

Approved

Treatment for adults with relapsed or refractory large B-cell lymphoma, approved in Korea in April 2026.

Completion reported

Received Korean marketing approval for the CAR-T therapy Limkato.

Official role guide

Curocell careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 1

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 큐로셀, 림카토주 식약처 품목허가 승인 ↗네이트 뉴스 · Published 2026-04-29 · Sources checked 2026-11-15 · Original unavailable